⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2347094 | 0.78 | — | — | |
| SCHEMBL457134 | 0.78 | — | — | |
| SCHEMBL1144496 | 0.74 | — | — | |
| SCHEMBL27694534 | 0.74 | — | — | |
| SCHEMBL29076221 | 0.74 | — | — | |
| SCHEMBL1144662 | 0.74 | — | — | |
| SCHEMBL3700282 | 0.67 | ACHE (0.30) | — | |
| SCHEMBL455868 | 0.67 | MEN1 (0.31) | — | |
| SCHEMBL3126523 | 0.67 | — | — | |
| SCHEMBL1144540 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230120707-A1 | Compounds and Method of Treating COVID-19 | PFIZER INC. (US) | 2023-04-20 | — | — | US | claimed |
| CN-101472924-A | KV1.5 potassium channel inhibitors | WYETH CORP (US) | 2009-07-01 | — | — | CN | claimed |
| EP-2035420-A2 | KV1.5 POTASSIUM CHANNEL INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | claimed |
| US-7402589-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-07-22 | — | — | US | claimed |
| WO-2007149873-A2 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | WO | claimed |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| CN-1946700-A | Trisubstituted ureas as cytokine inhibitors | PROCTER & GAMBLE (US) | 2007-04-11 | — | — | CN | claimed |
| EP-1737830-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005105757-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | claimed |
| US-20230120707-A1 | Compounds and Method of Treating COVID-19 | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3045450-A1 | INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-2614053-B1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| EP-2247575-B1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-03-23 | — | — | EP | disclosed |
| WO-2007149873-A2 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | WO | disclosed |
| CN-1946700-A | Trisubstituted ureas as cytokine inhibitors | PROCTER & GAMBLE (US) | 2007-04-11 | — | — | CN | disclosed |
| EP-1737830-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005105757-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | disclosed |